Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.

Hematology (Amsterdam, Netherlands) - 1 Dec 2009

Basquiera Ana L, Soria Néstor W, Ryser Ricardo, Salguero Miriam, Moiraghi Beatriz, Sackmann Federico, Sturich Ana G, Borello Adriana, Berretta Adriana, Bonafé Miriam, Barral José Moreno, Palazzo Emilio D, García Juan J

Abstract excerpt

OBJECTIVE: To determine the prevalence of JAK2 V617F mutation and its clinical correlation in patients with chronic myeloproliferative disorders (CMD): polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). MATERIALS AND METHODS: Detection of JAK2 V617F mutation by allele specific-PCR. RESULTS: One hundred and three patients with CMD were included in the study. JAK2 V617F...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Amino Acid Substitution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chronic Disease

Share to Janus Kinase 2

Share to Mutation, Missense

Share to Myeloproliferative Disorders

Share to Polymerase Chain Reaction

Share to Thrombosis

Source

Identifiers

PMID: 19941738
DOI: 10.1179/102453309X12473408860226

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.PMID 19941738Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.Semantic proximity Read ↗

[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].Semantic proximity Read ↗

The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.Semantic proximity Read ↗

Familial chronic myeloproliferative disorders: the state of the art.Semantic proximity Read ↗

Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

[Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.